GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Cyclically Adjusted PS Ratio

Sumitomo Pharma Co (Sumitomo Pharma Co) Cyclically Adjusted PS Ratio : (As of May. 15, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sumitomo Pharma Co Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sumitomo Pharma Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sumitomo Pharma Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Cyclically Adjusted PS Ratio Chart

Sumitomo Pharma Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.33 1.79 1.06 0.66 -

Sumitomo Pharma Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.52 0.44 0.38 -

Competitive Comparison of Sumitomo Pharma Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Cyclically Adjusted PS Ratio falls into.



Sumitomo Pharma Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Sumitomo Pharma Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.336/107.2000*107.2000
=1.336

Current CPI (Mar. 2024) = 107.2000.

Sumitomo Pharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.213 98.000 2.421
201409 2.075 98.500 2.258
201412 2.127 97.900 2.329
201503 1.928 97.900 2.111
201506 1.996 98.400 2.175
201509 2.112 98.500 2.299
201512 2.185 98.100 2.388
201603 2.199 97.900 2.408
201606 2.473 98.100 2.702
201609 2.339 98.000 2.559
201612 2.331 98.400 2.539
201703 2.293 98.100 2.506
201706 2.636 98.500 2.869
201709 2.617 98.800 2.839
201712 2.759 99.400 2.976
201803 2.651 99.200 2.865
201806 2.651 99.200 2.865
201809 2.475 99.900 2.656
201812 2.708 99.700 2.912
201903 2.545 99.700 2.736
201906 2.736 99.800 2.939
201909 2.648 100.100 2.836
201912 2.916 100.500 3.110
202003 2.939 100.300 3.141
202006 3.132 99.900 3.361
202009 3.043 99.900 3.265
202012 3.232 99.300 3.489
202103 2.806 99.900 3.011
202106 2.999 99.500 3.231
202109 3.714 100.100 3.977
202112 3.059 100.100 3.276
202203 2.716 101.100 2.880
202206 3.004 101.800 3.163
202209 2.800 103.100 2.911
202212 2.630 104.100 2.708
202303 1.794 104.400 1.842
202306 1.348 105.200 1.374
202309 1.310 106.200 1.322
202312 1.440 106.800 1.445
202403 1.336 107.200 1.336

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sumitomo Pharma Co  (OTCPK:DNPUF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sumitomo Pharma Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.